At-home full-body stimulation suit to manage spasticity and ataxia in MS

Home-Based Neuromodulation Suits for Reducing Spasticity and Ataxia in Multiple Sclerosis: A Multi-center RCT

Not applicable Interventional Universitair Ziekenhuis Brussel · NCT07202195

This project will try whether wearing a full-body electrical stimulation suit for six weeks helps people with MS who have spasticity or ataxia reduce symptoms and improve daily functioning.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment70 (estimated)
Ages18 Years and up
SexAll
SponsorUniversitair Ziekenhuis Brussel Academic / other
Locations2 sites (Steenokkerzeel and 1 other locations)
Trial IDNCT07202195 on ClinicalTrials.gov

What this trial studies

The study compares two groups of people with MS: an intervention group who will wear a full-body electrostimulation suit and a control group who will receive usual care. Intervention participants wear the suit during a one-week admission at the MS center and then at home for five additional weeks, using it daily or every other day. Clinical tests are performed at the MS center after 1 week and after 6 weeks to measure spasticity, ataxia, and functional changes. Usual care continues for both groups throughout the study.

Who should consider this trial

Good fit: Adults with a confirmed diagnosis of multiple sclerosis who have spasticity (MAS ≥ 1) or ataxia (SARA ≥ 4) and who can understand instructions and complete questionnaires are the intended participants.

Not a fit: People with implanted electronic devices, recent relapse or recent changes in disease-modifying treatment, recent Botulinum toxin A, acute musculoskeletal problems, or insufficient cognitive ability are unlikely to be eligible or to benefit.

Why it matters

Potential benefit: If successful, the suit could reduce muscle stiffness and improve coordination and everyday mobility for people with MS.

How similar studies have performed: Small studies of targeted electrical neuromodulation have shown mixed benefits for MS symptoms, but full-body stimulation suits are a relatively novel approach with limited published evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Eligible participants must have ataxia or spasticity alongside impairments in upper or lower extremity physical function. MAS score ≥ 1 will be used as an inclusion criterion to determine the presence of spasticity. SARA score ≥ 4 will be used as an inclusion criterion to determine the presence of ataxia. Note: one of the two criteria (MAS score or SARA score) must be fulfilled for a pwMS to be eligible.
* The patient must have the cognitive abilities to understand instructions and to be able to complete the questionnaires adequately
* Diagnosis of multiple sclerosis.

Exclusion Criteria:

* Implanted devices (like pacemaker, Baclofen pump, neurostimulator, defibrillator, shunts, ECG equipment, electronic life support, high frequency operation equipment )
* Change in disease modifying treatment within the last 3 months
* Use of Botuline Toxine A within the last 3months
* Recent relapse within the last 3 months
* Acute musculoskeletal problems that hinder the test performance,
* Pregnancy
* Sizes bigger than 3XL (triple eXtra Large)
* Skin eruptions and/or skin areas in the stimulation zone that are swollen, infected or inflamed.

Where this trial is running

Steenokkerzeel and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Multiple SclerosisMSSpasticity With Multiple SclerosisAtaxia - OtherAtaxia, CerebellarAtaxia, MotorSpasticityHome Based Care
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.